trending Market Intelligence /marketintelligence/en/news-insights/trending/WCfjJVemQ80TsMlX3rwHOw2 content esgSubNav
In This List

Biofrontera responds to court order in dispute with Sun Pharmaceutical's US unit

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Biofrontera responds to court order in dispute with Sun Pharmaceutical's US unit

Biofrontera AG said the recently issued court order in its ongoing litigation with a Sun Pharmaceutical Industries Ltd. unit does not stop the company from marketing and selling its products to all current and potential customers.

DUSA Pharmaceuticals Inc., a unit of Sun Pharmaceutical, had asked the U.S. District Court of Massachusetts in November for a preliminary injunction order against Biofrontera, but the request was largely rejected by the court, Biofrontera said in a Dec. 27 news release.

According to Biofrontera, the court rejected DUSA's request to collect and image computing devices from Biofrontera employees and to restrain Biofrontera from contacting certain customers.

Leverkusen, Germany-based Biofrontera said it stopped using certain documents that appear to contain DUSA information. None of the documents identified in the case contain DUSA confidential information or DUSA trade secrets. The documents identified are also not vital to its ongoing operations or strategic growth, the company said.

Biofrontera said it will continue to defend itself against DUSA's allegations that the Biofrontera companies infringed on its patents for its topical medication, Levulan Kerastick, and the specific wavelength light emitter, Blu-U Blue Light, used in photodynamic therapy.